Symptomatic

Vestibular suppressants

The drugs that quiet an acute vertiginous storm. They buy comfort and function in the first few days — and then they get out of the way, because the same suppression that helps acutely slows recovery if it lingers.

What they do — and don’t

A vestibular suppressant dampens vestibular input to the central nervous system, easing vertigo, motion sensitivity and the autonomic storm of nausea and vomiting. It does not treat the underlying disorder. Use is normally restricted to the first 3–5 days of an episode, because prolonged administration impairs vestibular compensation and prolongs recovery.1,2

Receptor targets of the vestibular suppressants
ReceptorCNS siteDrug classEffect
H1 (histaminergic)Vestibular nuclei, chemoreceptor trigger zoneAntihistamines (meclizine, dimenhydrinate…)Blocks abnormal afferent vestibular signalling and nausea
M1 (muscarinic)Vestibular nuclei, reticular formation, CTZAnticholinergics (scopolamine); antihistamines (partial)Suppresses sensory-mismatch transmission and motion sickness
GABA-AVestibular nuclei, reticular formationBenzodiazepines (diazepam, lorazepam, clonazepam)Hyperpolarises neurons → damps excessive vestibular firing
D2 (dopaminergic)Chemoreceptor trigger zoneDopamine antagonists (prochlorperazine, metoclopramide)Antiemetic — reduces nausea and vomiting
Antiemetic and anti-vertigo effects converge on the vestibular nuclei and the chemoreceptor trigger zone. The same receptor blockade that helps acutely also produces the sedation and anticholinergic load that limit these drugs.

Antihistamines

The most commonly prescribed suppressants. They are H1 antagonists — usually with anticholinergic and sedative properties — that block histaminergic signalling in the vestibular nuclei and chemoreceptor trigger zone, and muscarinic transmission in the brainstem, interrupting the sensory-mismatch signals read as vertigo or motion sickness.1

  • Meclizine (25–50 mg 2–3×/day) — long-acting, comparatively low sedation; preferred for ambulatory patients.
  • Dimenhydrinate (50–100 mg every 4–6 h) — fast, reliable, but markedly sedating.
  • Promethazine (12.5–25 mg PO/IM) — potent antiemetic for intractable nausea, at the cost of deep sedation and extrapyramidal risk.
  • Diphenhydramine (25–50 mg) — effective but high anticholinergic load; avoid in older adults.

The evidence is for symptom control, not for accelerating recovery: trials show modest short-term reduction of vertigo and nausea in neuritis and labyrinthitis, with no benefit to compensation beyond the acute phase. Common side effects — drowsiness, dry mouth, blurred vision, urinary retention — can precipitate delirium and falls in the elderly.3

Anticholinergics

Scopolamine (hyoscine) blocks M1 muscarinicreceptors in the vestibular nuclei, reticular formation and CTZ. Delivered as a transdermal patch (1.5 mg / 72 h behind the ear), it is effective for motion-sickness prophylaxis but has little role in Ménière’s, neuritis or migraine. Its central antimuscarinic action causes confusion, delirium, hallucinations and memory impairment — pronounced in older or cognitively vulnerable patients — plus dry mouth, blurred vision and urinary retention. It is best reserved for short-term motion-sickness prophylaxis in younger, healthy individuals.1

Benzodiazepines

Trainee

Benzodiazepines potentiate GABA-A transmission, hyperpolarising neurons and suppressing excess firing in the vestibular nuclei. Diazepam (2–10 mg BD), lorazepam (0.5–2 mg BD) and clonazepam (0.25–0.5 mg BD) reduce the intensity of acute attacks, and their anxiolytic effect helps when dizziness is amplified by panic.1

Dopamine antagonists

Prochlorperazine (5–10 mg PO/IM TID) and metoclopramide (10 mg TID) are effective antiemetics for vertigo-induced nausea, blocking D2 receptors in the chemoreceptor trigger zone. Their main hazard is extrapyramidal symptoms — dystonia and parkinsonism — especially with prolonged use or in children, so they are best reserved for short-term use during severe acute attacks.5

Key points

  • Suppressants relieve acute symptoms only — they do not treat the cause.
  • Four classes: antihistamines (H1), anticholinergics (M1), benzodiazepines (GABA-A), dopamine antagonists (D2).
  • Meclizine is the workhorse antihistamine; scopolamine is for motion sickness; benzodiazepines for the severe acute attack.
  • All can cause sedation and falls — be especially cautious in older adults.
  • Limit to 3–5 days: prolonged use delays compensation and must not replace rehabilitation.